Kevin Regner Lab

The primary goal of the Regner laboratory is to investigate the cellular, molecular, and genetic mechanisms involved in ischemic acute kidney injury (AKI) and kidney repair.

Kevin R. Regner, MD, MS, FASN

Chief and Professor, Department of Medicine
kregner@mcw.edu

Current projects include:

Activator of G Protein Signaling 3 in Ischemic Renal Injury. The objective of this study is to characterize the role of Activator of G protein signaling 3 (AGS3), a novel non-receptor regulator of G-protein function, in renal tubular regeneration following ischemic AKI.

Genetic mapping and gene identification for acute kidney injury in outbred rats. The objective of this study is to identify novel genes that modulate susceptibility or resistance to AKI using a novel genetic resource, heterogeneous stock rats.

Bohan Xing, BS
Research Technologist I |
bxing@mcw.edu

Utilizing the murine model of renal ischemia-reperfusion injury, Bohan characterizes renal injury using molecular and biochemical assays and histological analysis.

Identification of cell division cycle protein 20 in various forms of acute and chronic kidney injury in mice.

(Swanson M, Yun J, Collier DM, Seif C, Yang CY, Regner KR, Park F.) Am J Physiol Renal Physiol. 2023 Aug 01;325(2):F248-F261 PMID: 37348027 SCOPUS ID: 2-s2.0-85165546515 06/22/2023
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.

(Patidar KR, Belcher JM, Regner KR, St Hillien SA, Simonetto DA, Asrani SK, Neyra JA, Sharma P, Velez JCQ, Wadei H, Nadim MK, Chung RT, Seethapathy R, Parada XV, Ouyang T, Ufere NN, Robinson JE, McLean Diaz P, Wilechansky RM, Przybyszewski EM, Smith TN, Ali AA, Orman ES, Schulz P, Siddiqui SM, Shabbir R, Liu LJ, Cama-Olivares A, Flannery AH, Baker ML, Gunasekaran D, Aswine A, Issa R, Li J, Verma S, Chalmers D, Varghese V, Lam W, Mohamed M, Kovacic R, Gaddy A, Attieh RM, Cortes P, Semnani S, Wang L, Khemichian S, Allegretti AS, from the HRS-HARMONY consortium.) J Hepatol. 2023 Jul 28 PMID: 37517455 SCOPUS ID: 2-s2.0-85171850314 07/31/2023
Update on Assessment of Estimated Glomerular Filtration Rate in Patients With Cirrhosis.

(Griffin C, Asrani SK, Regner KR.) Adv Kidney Dis Health. 2023 Jul;30(4):307-314 PMID: 37389536 06/30/2023
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1.

(Velez JCQ, Karakala N, Tayebi K, Wickman TJ, Mohamed MMB, Kovacic RA, Therapondos G, Kanduri SR, Allegretti AS, Belcher JM, Regner KR, Wentowski C.) Kidney360. 2023 Apr 01;4(4):e448-e456 PMID: 36763632 PMCID: PMC10278824 SCOPUS ID: 2-s2.0-85161650241 02/11/2023
Cannabinoid Type 2 Receptor Activation Reduces the Progression of Kidney Fibrosis Using a Mouse Model of Unilateral Ureteral Obstruction.

(Swanson ML, Regner KR, Moore BM 2nd, Park F.) Cannabis Cannabinoid Res. 2022 Dec;7(6):790-803 PMID: 35196117 SCOPUS ID: 2-s2.0-85147378966 02/24/2022
p66Shc signaling does not contribute to tubular damage induced by renal ischemia-reperfusion injury in rat

(Miller B, Regner K, Sorokin A.) Biochemical and Biophysical Research Communications. 7 May 2022;603:69-74 SCOPUS ID: 2-s2.0-85125835040 05/07/2022
p66Shc signaling does not contribute to tubular damage induced by renal ischemia-reperfusion injury in rat.

(Miller B, Regner K, Sorokin A.) Biochem Biophys Res Commun. 2022 May 07;603:69-74 PMID: 35278882 PMCID: PMC8969123 SCOPUS ID: 2-s2.0-85125835040 03/13/2022
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.

(Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, HRS-HARMONY Study Investigators.) Am J Kidney Dis. 2022 May;79(5):737-745 PMID: 34606933 SCOPUS ID: 2-s2.0-85122545748 10/05/2021
Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions.

(Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M.) Kidney Int. 2022 Apr;101(4):766-778 PMID: 35114200 PMCID: PMC8940673 SCOPUS ID: 2-s2.0-85125312317 02/04/2022
DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity.

(Hama T, Nagesh PK, Chowdhury P, Moore BM 2nd, Yallapu MM, Regner KR, Park F.) JCI Insight. 2021 Nov 22;6(22) PMID: 34806647 PMCID: PMC8663775 SCOPUS ID: 2-s2.0-85120382452 11/23/2021
Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study.

(Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St Hillien SA, Kalim S, Nigwekar SU, Flood JG, Nixon A, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Regner KR, Belcher JM, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, HRS-HARMONY study investigators.) Clin Transl Gastroenterol. 2021 May 11;12(5):e00359 PMID: 33979307 PMCID: PMC8116001 SCOPUS ID: 2-s2.0-85105838703 05/13/2021
DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity

(Hama T, Nagesh PKB, Chowdhury P, Moore BM, Yallapu MM, Regner KR, Park F.) JCI Insight. 22 November 2021;6(22) SCOPUS ID: 2-s2.0-85120382452 11/22/2021

Kevin Regner Lab

Kevin R. Regner, MD, MS, FASN

Recent Publications